Last updated: February 27, 2026
What Is the Drug Indicated For?
The NDC 00536-1052 corresponds to Rebif (interferon beta-1a), used primarily in treatment of multiple sclerosis (MS). Rebif is an injectable immunomodulator designed to reduce frequency and severity of MS relapses.
Market Size and Demand Drivers
Multiple Sclerosis Market Overview
- Estimated global MS population: 2.8 million (WHO, 2021)
- U.S. MS patient population: approximately 1 million (National Multiple Sclerosis Society, 2022)
- Growth rate: 2-3% annually due to increasing diagnosis and awareness
Rebif’s Position in the Market
- Market share among MS therapies: approximately 15-20%
- Key competitors: Avonex, Plegridy, Copaxone, Tecfidera, Tysabri
- Rebif’s niche: once-weekly interferon therapy
Regulatory and Reimbursement Environment
- FDA approval since 1996
- Reimbursed by major insurers and Medicaid in the U.S.
- Market access influenced by biosimilar entry and direct-acting oral MS drugs
Market Trends & Competitive Dynamics
- Shift from injectable to oral therapies: increases pressure on rebates and pricing
- Biosimilar development: potential entry of biosimilar interferons, possibly reducing Rebif prices
- Patient preference for less frequent dosing schedules: may influence market share
Pricing Overview
Current Price Points (U.S. Market)
| Price Factor |
Details |
| Average wholesale price (AWP) per 22 mcg dose |
$4,500 - $5,000 |
| Average sales price (ASP) |
$3,600 - $4,200 per 22 mcg dose (estimated) |
| Reimbursement rate |
Varies by insurer; often covers 80-100% of cost |
| Out-of-pocket cost |
$30 - $200 depending on deductible and copay |
Pricing Comparison with Competitors
| Drug |
Dosing Frequency |
Approximate Per-Dose Cost |
Market Position |
| Rebif (interferon beta-1a) |
Weekly |
$4,500 - $5,000 |
Moderate price, established brand |
| Avonex (interferon beta-1a) |
Weekly |
$3,500 - $4,000 |
Similar efficacy, lower price |
| Plegridy (interferon beta-1a) |
Every 14 days |
$5,000 - $6,000 |
Longer dosing, higher price |
| Ocrevus (ocrelizumab) |
Every 6 months |
$65,000 per infusion |
Biologic with higher annual cost |
Price Projections (Next 5 Years)
Factors Influencing Prices
- Biosimilar competition: Entry expected within 3-5 years
- Investment in formulation and delivery innovations
- Changes in healthcare policies and drug pricing regulations
- Patient and insurer shifts toward oral and biologic options
Predicted Pricing Trends
| Year |
Estimated Average Wholesale Price (per 22 mcg dose) |
Notes |
| 2023 |
$4,700 - $5,200 |
Current market prices |
| 2024 |
$4,400 - $4,900 (with biosimilar competition anticipated) |
Slight decline due to biosimilar entry and biosimilar pricing strategies |
| 2025 |
$4,200 - $4,700 |
Continued price erosion; increased market share of biosimilars |
| 2026 |
$4,000 - $4,500 |
Market stabilization with biosimilar proliferation |
| 2027 |
$3,800 - $4,200 |
Further price adjustments; emphasis on value-based contracting |
Key Drivers of Pricing Dynamics
- Biosimilar manufacturing costs and pricing strategies
- Regulatory policies favoring cost containment
- Competitive drug launches and patent expirations
- Adoption rates of oral MS therapies impacting injectable drug demand
Revenue Impact for Stakeholders
- Manufacturers’ revenue depends on market penetration and pricing strategies
- Payers aim for reduced drug costs via biosimilar adoption
- Patients face variable copays; impacted by insurance formulary placements
Summary
Rebif (NDC 00536-1052) operates within a mature MS treatment segment characterized by stable pricing, competitive pressure from biosimilars, and a shift toward oral therapies. Current average wholesale prices hover around $4,700 - $5,200 per 22 mcg dose. Price erosion is projected to continue at a moderate rate over the next five years, influenced primarily by biosimilar competition and healthcare policy reforms.
Key Takeaways
- Market is mature with stable demand driven by MS prevalence.
- Rebif holds a significant share but faces growth constraints from oral DMDs.
- Biosimilar entry will likely reduce prices by 10-20% over the coming years.
- Price projections indicate a gradual decline to below $4,000 per dose by 2027.
- Stakeholders should monitor regulatory, biosimilar, and reimbursement developments for strategic planning.
FAQs
Q1: When are biosimilars for interferon beta-1a expected to enter the market?
A1: Biosimilar versions are anticipated to launch within 3-5 years, potentially around 2025-2026.
Q2: How does Rebif’s dosing schedule influence its market share?
A2: Weekly dosing offers convenience, but longer dosing intervals with competitors may attract patients seeking less frequent injections.
Q3: What is the impact of biosimilar entry on Rebif’s pricing?
A3: Biosimilar entry is likely to exert downward pressure, reducing Rebif’s price by approximately 10-20% within 2-3 years.
Q4: Are there opportunities for premium pricing strategies?
A4: Limited; market trends favor price competition and biosimilars, which are typically priced lower.
Q5: How do regulatory policies affect future pricing?
A5: Policies promoting cost containment and biosimilar uptake could further decrease prices and margins.
References:
- World Health Organization. (2021). Multiple sclerosis prevalence estimates.
- National Multiple Sclerosis Society. (2022). MS facts and figures.
- IQVIA. (2022). U.S. drug pricing and sales data.
- FDA. (2020). Guidance on biosimilar approval pathways.
- EvaluatePharma. (2022). Drug market forecasts and pricing analysis.
